Most cited papers from Guardant (United States)

Guardant (United States)

What are the most cited papers from Guardant (United States)?

The most cited paper from Guardant (United States) is "Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer" (Seung Tae Kim et al., 2018), with 1,755 citations. Next come "Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA" (721) and "Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer" (612).

Published TypeFieldAccessCitations

Showing 50 of 60 papers. Every paper with more than 110 citations is listed.

Most cited papers, sortable by citations and release date
#	Paper
1	Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer Seung Tae Kim et al. · Nature Medicine	13 Jul 2018	1,755
2	Analytical and Clinical Validation of a Digital Sequencing Panel for Quantitative, Highly Accurate Evaluation of Cell-Free Circulating Tumor DNA Richard Burnham Lanman, Stefanie Mortimer, Oliver A. Zill et al. · PLoS ONE Open access	16 Oct 2015	721
3	Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung Cancer Natasha B. Leighl, Ray D. Page, Victoria M. Raymond et al. · Clinical Cancer Research	15 Apr 2019	612
4	Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers Collin Michael Blakely et al. · Nature Genetics Open access	6 Nov 2017	597
5	Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS–MAPK Reactivation Noritaka Tanaka, Jessica J. Lin, Chendi Li et al. · Cancer Discovery Open access	6 Apr 2021	535
6	Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project Diana M. Merino et al. · Journal for ImmunoTherapy of Cancer Open access	Mar 2020	516
7	Insights into RNA structure and function from genome-wide studies Stefanie Mortimer, Mary Anne Kidwell, Jennifer A. Doudna · Nature Reviews Genetics Review	13 May 2014	511
8	Structure-based classification predicts drug response in EGFR-mutant NSCLC Jacqulyne Ponville Robichaux et al. · Nature Open access	15 Sep 2021	491
9	Landscape of Acquired Resistance to Osimertinib in EGFR -Mutant NSCLC and Clinical Validation of Combined EGFR and RET Inhibition with Osimertinib and BLU-667 for Acquired RET Fusion Zofia Piotrowska et al. · Cancer Discovery Open access	26 Sep 2018	454
10	BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma Kevin Lin et al. · Cancer Discovery	13 Nov 2018	449
11	Validation of a Plasma-Based Comprehensive Cancer Genotyping Assay Utilizing Orthogonal Tissue- and Plasma-Based Methodologies Justin Iver Odegaard, John J. Vincent, Stefanie Mortimer et al. · Clinical Cancer Research	24 Apr 2018	445
12	Aberrant FGFR signaling mediates resistance to CDK4/6 inhibitors in ER+ breast cancer Luigi Formisano et al. · Nature Communications Open access	26 Mar 2019	432
13	Polyclonal RB1 mutations and acquired resistance to CDK 4/6 inhibitors in patients with metastatic breast cancer Rosaria Condorelli, Laura M. Spring, Joyce O’Shaughnessy et al. · Annals of Oncology Open access	8 Dec 2017	412
14	Nivolumab for previously treated unresectable metastatic anal cancer (NCI9673): a multicentre, single-arm, phase 2 study Van Karlyle Morris et al. · The Lancet Oncology Open access	18 Feb 2017	406
15	The Landscape of Actionable Genomic Alterations in Cell-Free Circulating Tumor DNA from 21,807 Advanced Cancer Patients Oliver A. Zill, Kimberly C. Banks, Stephen R. Fairclough et al. · Clinical Cancer Research	18 May 2018	397
16	Randomized Trial of Irinotecan and Cetuximab With or Without Vemurafenib in BRAF-Mutant Metastatic Colorectal Cancer (SWOG S1406) Scott Kopetz, Katherine Adams Guthrie, Van Karlyle Morris et al. · Journal of Clinical Oncology Open access	23 Dec 2020	394
17	Minimal Residual Disease Detection using a Plasma-only Circulating Tumor DNA Assay in Patients with Colorectal Cancer Aparna R. Parikh et al. · Clinical Cancer Research Open access	29 Apr 2021	385
18	Clinical utility of circulating tumor DNA sequencing in advanced gastrointestinal cancer: SCRUM-Japan GI-SCREEN and GOZILA studies Yoshiaki Nakamura et al. · Nature Medicine	5 Oct 2020	380
19	Real-time Genomic Characterization of Advanced Pancreatic Cancer to Enable Precision Medicine Andrew J. Aguirre et al. · Cancer Discovery Open access	14 Jun 2018	372
20	First-line pembrolizumab and trastuzumab in HER2-positive oesophageal, gastric, or gastro-oesophageal junction cancer: an open-label, single-arm, phase 2 trial Yelena Yuriy Janjigian et al. · The Lancet Oncology Open access	18 May 2020	365
21	Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer John H. Strickler, Jonathan M. Loree, Leanne G. Ahronian et al. · Cancer Discovery Open access	Dec 2017	312
22	Genomic Heterogeneity as a Barrier to Precision Medicine in Gastroesophageal Adenocarcinoma Eirini Pectasides et al. · Cancer Discovery Open access	4 Oct 2017	311
23	Cell-Free DNA Next-Generation Sequencing in Pancreatobiliary Carcinomas Oliver A. Zill, Claire C Greene, Dragan Sebisanovic et al. · Cancer Discovery Open access	24 Jun 2015	287
24	Anti-EGFR-resistant clones decay exponentially after progression: implications for anti-EGFR re-challenge Christine Megerdichian Parseghian et al. · Annals of Oncology Open access	17 Nov 2018	253
25	Pan-Cancer Landscape and Analysis of ERBB2 Mutations Identifies Poziotinib as a Clinically Active Inhibitor and Enhancer of T-DM1 Activity Jacqulyne Ponville Robichaux et al. · Cancer Cell Open access	Oct 2019	247
26	Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trial Yoshiaki Nakamura et al. · Nature Medicine Open access	Nov 2021	245
27	Validation of Microsatellite Instability Detection Using a Comprehensive Plasma-Based Genotyping Panel Jason A. Willis et al. · Clinical Cancer Research	Dec 2019	245
28	Tumor Genomic Profiling Guides Patients with Metastatic Gastric Cancer to Targeted Treatment: The VIKTORY Umbrella Trial Jeeyun Lee et al. · Cancer Discovery	17 Jul 2019	240
29	Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14–Mutant NSCLC Gonzalo Recondo et al. · Clinical Cancer Research	7 Feb 2020	229
30	Resistance to TRK inhibition mediated by convergent MAPK pathway activation Emiliano Cocco et al. · Nature Medicine Open access	12 Aug 2019	228
31	Phase IB Study of Vemurafenib in Combination with Irinotecan and Cetuximab in Patients with Metastatic Colorectal Cancer with BRAF V600E Mutation David S. Hong et al. · Cancer Discovery Open access	11 Oct 2016	220
32	Genomic Profiling of Advanced Non–Small Cell Lung Cancer in Community Settings: Gaps and Opportunities Martin E Gutierrez, Kelly Choi, Richard Burnham Lanman et al. · Clinical Lung Cancer Open access	13 Apr 2017	212
33	MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer Ibiayi Dagogo‐Jack et al. · Clinical Cancer Research Open access	21 Feb 2020	201
34	Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC Marcelo Vailati Negrao et al. · Cancer Discovery Open access	17 Apr 2023	200
35	Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial Daniel V.T. Catenacci et al. · The Lancet Oncology	9 Jul 2020	192
36	Neratinib Efficacy and Circulating Tumor DNA Detection of HER2 Mutations in HER2 Nonamplified Metastatic Breast Cancer Cynthia X. Ma et al. · Clinical Cancer Research Open access	5 Jul 2017	192
37	Spectrum of driver mutations and clinical impact of circulating tumor DNA analysis in non–small cell lung cancer: Analysis of over 8000 cases Philip C. Mack, Kimberly C. Banks, Carin R. Espenschied et al. · Cancer Open access	4 May 2020	184
38	Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors David Eric Piccioni, Achal Singh Achrol, Lesli Ann Kiedrowski et al. · CNS Oncology Open access	11 Mar 2019	172
39	Alterations in PTEN and ESR1 promote clinical resistance to alpelisib plus aromatase inhibitors Pedram Razavi et al. · Nature Cancer	23 Mar 2020	169
40	Cell-Free DNA and Circulating Tumor Cells: Comprehensive Liquid Biopsy Analysis in Advanced Breast Cancer Giovanna Rossi, Zhaomei Mu, ALFRED W. RADEMAKER et al. · Clinical Cancer Research	27 Nov 2017	164
41	Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer Giulia Siravegna et al. · Cancer Cell Open access	Jul 2018	162
42	Clinical Utility of Cell-Free DNA for the Detection of ALK Fusions and Genomic Mechanisms of ALK Inhibitor Resistance in Non–Small Cell Lung Cancer Caroline Elizabeth McCoach, Collin Michael Blakely, Kimberly C. Banks et al. · Clinical Cancer Research Open access	29 Mar 2018	155
43	Treatment with Next-Generation ALK Inhibitors Fuels Plasma ALK Mutation Diversity Ibiayi Dagogo‐Jack, Marguerite M. Rooney, Jessica J. Lin et al. · Clinical Cancer Research Open access	29 Jul 2019	152
44	Glesatinib Exhibits Antitumor Activity in Lung Cancer Models and Patients Harboring MET Exon 14 Mutations and Overcomes Mutation-mediated Resistance to Type I MET Inhibitors in Nonclinical Models Lars D. Engstrom et al. · Clinical Cancer Research	Aug 2017	150
45	Detection rate of actionable mutations in diverse cancers using a biopsy-free (blood) circulating tumor cell DNA assay Maria Clemence Schwaederle, Hatim Husain, Paul Timothy Fanta et al. · Oncotarget Open access	Feb 2016	149
46	EGFR and MET Amplifications Determine Response to HER2 Inhibition in ERBB2 -Amplified Esophagogastric Cancer Francisco Sánchez-Vega et al. · Cancer Discovery Open access	21 Nov 2018	148
47	Utility of Genomic Assessment of Blood-Derived Circulating Tumor DNA (ctDNA) in Patients with Advanced Lung Adenocarcinoma Maria Clemence Schwaederle, Sandip Pravin Patel, Hatim Husain et al. · Clinical Cancer Research Open access	24 May 2017	147
48	The clinical landscape of cell-free DNA alterations in 1671 patients with advanced biliary tract cancer J.E. Berchuck et al. · Annals of Oncology Open access	9 Sep 2022	146
49	Evolution of Circulating Tumor DNA Profile from First-line to Subsequent Therapy in Metastatic Renal Cell Carcinoma Sumanta Kumar Pal, Guru Sonpavde, Neeraj Agarwal et al. · European Urology	14 Apr 2017	142
50	Utility of Genomic Analysis In Circulating Tumor DNA from Patients with Carcinoma of Unknown Primary Shumei Kato, Nithya Krishnamurthy, Kimberly C. Banks et al. · Cancer Research Open access	22 Jun 2017	138

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.